nodes	percent_of_prediction	percent_of_DWPC	metapath
Methamphetamine—TAAR1—female reproductive system—cervical cancer	0.0524	0.0596	CbGeAlD
Methamphetamine—SLC18A1—vagina—cervical cancer	0.0504	0.0573	CbGeAlD
Methamphetamine—SLC18A1—lymph node—cervical cancer	0.0326	0.0371	CbGeAlD
Methamphetamine—SLC18A2—uterine cervix—cervical cancer	0.0238	0.027	CbGeAlD
Methamphetamine—SLC18A2—endometrium—cervical cancer	0.0215	0.0244	CbGeAlD
Methamphetamine—SLC18A2—uterus—cervical cancer	0.0198	0.0225	CbGeAlD
Methamphetamine—SLC18A2—female reproductive system—cervical cancer	0.0178	0.0202	CbGeAlD
Methamphetamine—SLC22A3—uterine cervix—cervical cancer	0.0169	0.0192	CbGeAlD
Methamphetamine—SLC18A2—vagina—cervical cancer	0.0161	0.0183	CbGeAlD
Methamphetamine—SLC22A3—renal system—cervical cancer	0.0158	0.018	CbGeAlD
Methamphetamine—TAAR1—Amine ligand-binding receptors—TAAR6—cervical cancer	0.0157	0.139	CbGpPWpGaD
Methamphetamine—MAOB—uterine cervix—cervical cancer	0.0157	0.0178	CbGeAlD
Methamphetamine—SLC22A3—endometrium—cervical cancer	0.0153	0.0174	CbGeAlD
Methamphetamine—MAOB—decidua—cervical cancer	0.0149	0.017	CbGeAlD
Methamphetamine—SLC22A3—mammalian vulva—cervical cancer	0.0148	0.0168	CbGeAlD
Methamphetamine—MAOB—renal system—cervical cancer	0.0146	0.0167	CbGeAlD
Methamphetamine—MAOB—endometrium—cervical cancer	0.0142	0.0161	CbGeAlD
Methamphetamine—SLC6A2—decidua—cervical cancer	0.0138	0.0157	CbGeAlD
Methamphetamine—MAOB—mammalian vulva—cervical cancer	0.0137	0.0156	CbGeAlD
Methamphetamine—MAOA—uterine cervix—cervical cancer	0.0134	0.0152	CbGeAlD
Methamphetamine—MAOB—uterus—cervical cancer	0.013	0.0148	CbGeAlD
Methamphetamine—ADRA2C—uterine cervix—cervical cancer	0.0128	0.0146	CbGeAlD
Methamphetamine—MAOA—decidua—cervical cancer	0.0127	0.0145	CbGeAlD
Methamphetamine—SLC22A3—female reproductive system—cervical cancer	0.0127	0.0144	CbGeAlD
Methamphetamine—MAOA—renal system—cervical cancer	0.0125	0.0142	CbGeAlD
Methamphetamine—SLC6A4—female reproductive system—cervical cancer	0.0123	0.014	CbGeAlD
Methamphetamine—SLC22A5—uterine cervix—cervical cancer	0.0123	0.014	CbGeAlD
Methamphetamine—ADRA2C—decidua—cervical cancer	0.0122	0.0139	CbGeAlD
Methamphetamine—MAOA—endometrium—cervical cancer	0.0121	0.0137	CbGeAlD
Methamphetamine—ADRA2C—renal system—cervical cancer	0.012	0.0137	CbGeAlD
Methamphetamine—MAOB—female reproductive system—cervical cancer	0.0117	0.0133	CbGeAlD
Methamphetamine—MAOA—mammalian vulva—cervical cancer	0.0117	0.0133	CbGeAlD
Methamphetamine—ADRA2C—endometrium—cervical cancer	0.0116	0.0132	CbGeAlD
Methamphetamine—SLC22A3—female gonad—cervical cancer	0.0115	0.0131	CbGeAlD
Methamphetamine—SLC22A5—renal system—cervical cancer	0.0115	0.0131	CbGeAlD
Methamphetamine—SLC22A3—vagina—cervical cancer	0.0115	0.013	CbGeAlD
Methamphetamine—ADRA2C—mammalian vulva—cervical cancer	0.0112	0.0128	CbGeAlD
Methamphetamine—MAOA—uterus—cervical cancer	0.0111	0.0127	CbGeAlD
Methamphetamine—SLC22A5—endometrium—cervical cancer	0.0111	0.0127	CbGeAlD
Methamphetamine—SLC6A2—female reproductive system—cervical cancer	0.0109	0.0124	CbGeAlD
Methamphetamine—ADRA2C—uterus—cervical cancer	0.0107	0.0122	CbGeAlD
Methamphetamine—MAOB—female gonad—cervical cancer	0.0107	0.0121	CbGeAlD
Methamphetamine—MAOB—vagina—cervical cancer	0.0106	0.0121	CbGeAlD
Methamphetamine—SLC18A2—lymph node—cervical cancer	0.0104	0.0118	CbGeAlD
Methamphetamine—ADRA2A—uterine cervix—cervical cancer	0.0102	0.0117	CbGeAlD
Methamphetamine—MAOA—female reproductive system—cervical cancer	0.01	0.0114	CbGeAlD
Methamphetamine—ADRA2A—decidua—cervical cancer	0.00976	0.0111	CbGeAlD
Methamphetamine—ADRA2A—endometrium—cervical cancer	0.00927	0.0105	CbGeAlD
Methamphetamine—SLC22A5—female reproductive system—cervical cancer	0.00922	0.0105	CbGeAlD
Methamphetamine—MAOA—female gonad—cervical cancer	0.00911	0.0104	CbGeAlD
Methamphetamine—MAOA—vagina—cervical cancer	0.00905	0.0103	CbGeAlD
Methamphetamine—ADRA2A—mammalian vulva—cervical cancer	0.00896	0.0102	CbGeAlD
Methamphetamine—ADRA2C—female gonad—cervical cancer	0.00875	0.00996	CbGeAlD
Methamphetamine—ADRA2C—vagina—cervical cancer	0.0087	0.0099	CbGeAlD
Methamphetamine—ADRA2A—uterus—cervical cancer	0.00854	0.00971	CbGeAlD
Methamphetamine—SLC22A5—female gonad—cervical cancer	0.00839	0.00954	CbGeAlD
Methamphetamine—SLC22A5—vagina—cervical cancer	0.00833	0.00948	CbGeAlD
Methamphetamine—ADRA2A—female reproductive system—cervical cancer	0.00768	0.00873	CbGeAlD
Methamphetamine—Lacosamide—CA9—cervical cancer	0.00759	1	CrCbGaD
Methamphetamine—CYP2D6—renal system—cervical cancer	0.00743	0.00845	CbGeAlD
Methamphetamine—SLC22A3—lymph node—cervical cancer	0.00741	0.00843	CbGeAlD
Methamphetamine—ADRA2A—female gonad—cervical cancer	0.00699	0.00795	CbGeAlD
Methamphetamine—ADRA2A—vagina—cervical cancer	0.00694	0.0079	CbGeAlD
Methamphetamine—MAOB—lymph node—cervical cancer	0.00686	0.0078	CbGeAlD
Methamphetamine—TAAR1—G alpha (s) signalling events—TAAR6—cervical cancer	0.0065	0.0574	CbGpPWpGaD
Methamphetamine—SLC6A2—lymph node—cervical cancer	0.00635	0.00723	CbGeAlD
Methamphetamine—ADRA2B—Platelet Aggregation (Plug Formation)—GP5—cervical cancer	0.00621	0.0548	CbGpPWpGaD
Methamphetamine—CYP2D6—female reproductive system—cervical cancer	0.00595	0.00676	CbGeAlD
Methamphetamine—MAOA—lymph node—cervical cancer	0.00585	0.00666	CbGeAlD
Methamphetamine—ADRA2C—Platelet Aggregation (Plug Formation)—GP5—cervical cancer	0.0058	0.0512	CbGpPWpGaD
Methamphetamine—ADRA2C—lymph node—cervical cancer	0.00563	0.0064	CbGeAlD
Methamphetamine—MAOB—Tryptophan metabolism—UBE3A—cervical cancer	0.0055	0.0486	CbGpPWpGaD
Methamphetamine—CYP2D6—female gonad—cervical cancer	0.00541	0.00615	CbGeAlD
Methamphetamine—SLC22A5—lymph node—cervical cancer	0.00539	0.00613	CbGeAlD
Methamphetamine—ADRA2A—Platelet Aggregation (Plug Formation)—GP5—cervical cancer	0.00471	0.0416	CbGpPWpGaD
Methamphetamine—ADRA2A—lymph node—cervical cancer	0.00449	0.00511	CbGeAlD
Methamphetamine—ADRA2B—Amine ligand-binding receptors—TAAR6—cervical cancer	0.00433	0.0383	CbGpPWpGaD
Methamphetamine—ADRA2C—Amine ligand-binding receptors—TAAR6—cervical cancer	0.00405	0.0357	CbGpPWpGaD
Methamphetamine—ADRA2A—Amine ligand-binding receptors—TAAR6—cervical cancer	0.00329	0.029	CbGpPWpGaD
Methamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.0031	0.0273	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR ligand binding—TAAR6—cervical cancer	0.00236	0.0208	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR ligand binding—WNT2—cervical cancer	0.00184	0.0163	CbGpPWpGaD
Methamphetamine—ADRA2B—Platelet activation, signaling and aggregation—GP6—cervical cancer	0.0017	0.015	CbGpPWpGaD
Methamphetamine—ADRA2C—Platelet activation, signaling and aggregation—GP6—cervical cancer	0.00159	0.014	CbGpPWpGaD
Methamphetamine—ADRA2B—Platelet activation, signaling and aggregation—GP5—cervical cancer	0.00149	0.0131	CbGpPWpGaD
Methamphetamine—SLC18A2—Dopaminergic Neurogenesis—STAT3—cervical cancer	0.00147	0.0129	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR ligand binding—WNT5A—cervical cancer	0.0014	0.0123	CbGpPWpGaD
Methamphetamine—ADRA2C—Platelet activation, signaling and aggregation—GP5—cervical cancer	0.00139	0.0123	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—TAAR6—cervical cancer	0.00133	0.0118	CbGpPWpGaD
Methamphetamine—SLC6A4—Circadian rythm related genes—UBE3A—cervical cancer	0.00129	0.0114	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—GP6—cervical cancer	0.00129	0.0114	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—TAAR6—cervical cancer	0.00121	0.0107	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—GP5—cervical cancer	0.00113	0.00995	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—WNT2—cervical cancer	0.000945	0.00834	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—AKAP13—cervical cancer	0.000913	0.00807	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—GP6—cervical cancer	0.000876	0.00774	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—SERPIND1—cervical cancer	0.000876	0.00774	CbGpPWpGaD
Methamphetamine—SLC6A3—Dopaminergic Neurogenesis—STAT3—cervical cancer	0.000874	0.00772	CbGpPWpGaD
Methamphetamine—SLC6A3—Parkinsons Disease Pathway—CASP3—cervical cancer	0.000861	0.0076	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.000852	0.00752	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—AKAP13—cervical cancer	0.000829	0.00732	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—SERPIND1—cervical cancer	0.000818	0.00723	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—GP6—cervical cancer	0.000818	0.00723	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.000796	0.00703	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—GP5—cervical cancer	0.000766	0.00676	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—WNT5A—cervical cancer	0.000716	0.00632	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—GP5—cervical cancer	0.000715	0.00632	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—TAAR6—cervical cancer	0.000715	0.00631	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—HES1—cervical cancer	0.000702	0.0062	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—SERPIND1—cervical cancer	0.000665	0.00587	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—GP6—cervical cancer	0.000665	0.00587	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—TAAR6—cervical cancer	0.000649	0.00573	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.000646	0.00571	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—TAAR6—cervical cancer	0.000606	0.00535	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—GP5—cervical cancer	0.000581	0.00513	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—HES1—cervical cancer	0.000575	0.00508	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—WNT2—cervical cancer	0.000558	0.00493	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—WNT2—cervical cancer	0.000507	0.00447	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—TAAR6—cervical cancer	0.000492	0.00435	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—AKAP13—cervical cancer	0.00049	0.00433	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—WNT2—cervical cancer	0.000473	0.00418	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—WNT5A—cervical cancer	0.000423	0.00373	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—WNT2—cervical cancer	0.000384	0.00339	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—WNT5A—cervical cancer	0.000384	0.00339	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—TAAR6—cervical cancer	0.000367	0.00324	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—CASP3—cervical cancer	0.000365	0.00322	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—WNT5A—cervical cancer	0.000359	0.00317	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—CTNNB1—cervical cancer	0.000352	0.00311	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—TAAR6—cervical cancer	0.000343	0.00302	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—TAAR6—cervical cancer	0.000333	0.00294	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—CA9—cervical cancer	0.000314	0.00277	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—TAAR6—cervical cancer	0.000311	0.00275	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—CASP3—cervical cancer	0.000299	0.00264	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—NOTCH2—cervical cancer	0.000297	0.00262	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—WNT5A—cervical cancer	0.000291	0.00257	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—CTNNB1—cervical cancer	0.000288	0.00255	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—TAAR6—cervical cancer	0.000278	0.00246	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—CA9—cervical cancer	0.000266	0.00235	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—WNT2—cervical cancer	0.00026	0.0023	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—TAAR6—cervical cancer	0.000253	0.00223	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—AKAP13—cervical cancer	0.000251	0.00222	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—HES1—cervical cancer	0.000243	0.00215	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—WNT2—cervical cancer	0.000243	0.00214	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—AKAP13—cervical cancer	0.000235	0.00207	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—AKAP13—cervical cancer	0.000228	0.00202	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—TERT—cervical cancer	0.000213	0.00188	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—AKAP13—cervical cancer	0.000213	0.00188	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—WNT2—cervical cancer	0.000197	0.00174	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—WNT5A—cervical cancer	0.000197	0.00174	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—CA9—cervical cancer	0.000197	0.00174	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TAAR6—cervical cancer	0.000197	0.00174	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—FGFR3—cervical cancer	0.000196	0.00173	CbGpPWpGaD
Methamphetamine—SLC6A4—Circadian rythm related genes—TP53—cervical cancer	0.000191	0.00169	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—AKAP13—cervical cancer	0.000191	0.00168	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—WNT5A—cervical cancer	0.000184	0.00163	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TAAR6—cervical cancer	0.000184	0.00162	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—NOTCH1—cervical cancer	0.000184	0.00162	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—AKAP13—cervical cancer	0.000173	0.00153	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—EGFR—cervical cancer	0.000164	0.00145	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CA9—cervical cancer	0.000162	0.00143	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—WNT2—cervical cancer	0.000154	0.00136	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—WNT5A—cervical cancer	0.000149	0.00132	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TAAR6—cervical cancer	0.000149	0.00132	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—WNT2—cervical cancer	0.000143	0.00127	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—MTOR—cervical cancer	0.000138	0.00122	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—AKAP13—cervical cancer	0.000135	0.00119	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CA9—cervical cancer	0.000132	0.00116	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—MTHFR—cervical cancer	0.000127	0.00112	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CASP3—cervical cancer	0.000127	0.00112	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—AKAP13—cervical cancer	0.000126	0.00111	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CTNNB1—cervical cancer	0.000122	0.00108	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—WNT2—cervical cancer	0.000117	0.00103	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—WNT5A—cervical cancer	0.000116	0.00103	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—WNT5A—cervical cancer	0.000109	0.00096	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—MTHFR—cervical cancer	0.000108	0.000952	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—STAT3—cervical cancer	0.000106	0.00094	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—AKAP13—cervical cancer	0.000102	0.000903	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—EGFR—cervical cancer	9.67e-05	0.000854	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—WNT5A—cervical cancer	8.83e-05	0.00078	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CA9—cervical cancer	8.57e-05	0.000757	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NOTCH2—cervical cancer	8.17e-05	0.000721	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—TP53—cervical cancer	8.12e-05	0.000717	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—MTHFR—cervical cancer	7.99e-05	0.000706	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NOTCH2—cervical cancer	7.63e-05	0.000674	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—HES1—cervical cancer	6.7e-05	0.000591	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—TP53—cervical cancer	6.59e-05	0.000582	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—MTHFR—cervical cancer	6.57e-05	0.000581	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—HES1—cervical cancer	6.26e-05	0.000552	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NOTCH2—cervical cancer	6.2e-05	0.000547	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—TP53—cervical cancer	6.16e-05	0.000544	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TERT—cervical cancer	5.87e-05	0.000518	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TERT—cervical cancer	5.48e-05	0.000484	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—FGFR3—cervical cancer	5.39e-05	0.000476	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—MTHFR—cervical cancer	5.34e-05	0.000472	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—HES1—cervical cancer	5.08e-05	0.000449	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NOTCH1—cervical cancer	5.06e-05	0.000446	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—FGFR3—cervical cancer	5.03e-05	0.000444	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—TP53—cervical cancer	5e-05	0.000442	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NOTCH1—cervical cancer	4.72e-05	0.000417	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—EGFR—cervical cancer	4.5e-05	0.000398	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TERT—cervical cancer	4.45e-05	0.000393	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—EGFR—cervical cancer	4.21e-05	0.000372	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—FGFR3—cervical cancer	4.09e-05	0.000361	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NOTCH1—cervical cancer	3.84e-05	0.000339	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MTOR—cervical cancer	3.79e-05	0.000335	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MTOR—cervical cancer	3.54e-05	0.000313	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CASP3—cervical cancer	3.48e-05	0.000308	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—MTHFR—cervical cancer	3.48e-05	0.000307	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—EGFR—cervical cancer	3.42e-05	0.000302	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CTNNB1—cervical cancer	3.36e-05	0.000297	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CASP3—cervical cancer	3.25e-05	0.000287	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CTNNB1—cervical cancer	3.14e-05	0.000277	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—STAT3—cervical cancer	2.93e-05	0.000259	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MTOR—cervical cancer	2.87e-05	0.000254	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—STAT3—cervical cancer	2.73e-05	0.000242	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—EGFR—cervical cancer	2.66e-05	0.000235	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CASP3—cervical cancer	2.64e-05	0.000233	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CTNNB1—cervical cancer	2.55e-05	0.000225	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—EGFR—cervical cancer	2.49e-05	0.00022	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TP53—cervical cancer	2.23e-05	0.000197	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—STAT3—cervical cancer	2.22e-05	0.000196	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TP53—cervical cancer	2.09e-05	0.000184	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—EGFR—cervical cancer	2.02e-05	0.000178	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TP53—cervical cancer	1.7e-05	0.00015	CbGpPWpGaD
